As of May 26
| -0.10 / -4.35%|
The 2 analysts offering 12-month price forecasts for DelMar Pharmaceuticals Inc have a median target of 11.50, with a high estimate of 12.00 and a low estimate of 11.00. The median estimate represents a +422.73% increase from the last price of 2.20.
The current consensus among 2 polled investment analysts is to Buy stock in DelMar Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.